Trial results

A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

NCT07812597 on ClinicalTrials.gov · last registry update 2026-09-10

Registered but not yet open, with 210 participants planned. Due to report 13 January 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Beijing QL Biopharmaceutical Co.,Ltd

Sponsor type

Industry

Enrollment

210

Started

2026-10-12

Primary completion

2028-01-13 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.